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OBJECTIVES: Compliance with antihypertensives is inﬂuenced
by various factors, and inﬂuences blood pressure (BP) control
and cardiovascular outcomes. Differences in compliance, eg. the
improvement associated with ﬁxed-dose combinations (FDCs),
are acknowledged, but have not been incorporated into cost-
effectiveness modeling because the chain of causality between
compliance and outcomes is complex. We developed a method to
quantify this chain of effects which can use simple compliance
parameters such as medication possession ratios, or more sophis-
ticated inputs; it can also be tailored to speciﬁc decision prob-
lems. METHODS: First the effect of variation in compliance on
simulated dosing histories is modeled. Second, the rate of fall/
rise in BP on initiating/withdrawing treatment, and the full-
compliance BP reduction, are used to estimate corresponding BP
trajectories. Finally clinical endpoints are modeled from these
BP trajectories, based on existing evidence. In an illustrative
example, the effect of choosing an FDC over the corresponding
component-based regime was modeled. The FDC effect was
modeled as an 11% reduction in missed doses [reference], dis-
tributed evenly across interruptions of different lengths. Systolic
blood pressure (SBP) trajectories were estimated assuming bio-
equivalence between FDC and component-based regimes, and
the mean SBP calculated. The Framingham risk equation was
used to predict the number of strokes which would be expected
on the component-based regime, and the expected number which
FDC use would avoid through superior compliance. RESULTS:
This approach allows quantiﬁcation of compliance-mediated
health effects with great ﬂexibility. CONCLUSIONS: More
detailed data on the effects of FDC use on compliance can be
incorporated, and different treatment efﬁcacies and/or different
durations of action can be substituted, as can different BP
summary statistics, different clinical endpoints, and different
sources for the relationships between them. Reference: Taylor A
and Shoheiber O. Adherence to antihypertensive therapy with
ﬁxed-dose amplodipine besylate/benazepril versus comparable
component-based therapy. Congestive Heart Failure 2003;9:
324–32.
PCV123
THE CARDIOVASCULAR PREVENTION MODEL (CPM),A
GENERICALLY APPLICABLE MODEL FOR UNDERTAKING
COST-EFFECTIVENESS ANALYSES OF PREVENTIVE
INTERVENTIONS
Liew D1, Nanayakkara S2,Webb K3, Grobler M4, Delahoy PJ5,
Magliano DJ6
1The University of Melbourne, Melbourne,Victoria, Australia, 2Monash
University, Melbourne,Victoria, Australia, 3Pﬁzer Inc,Tadworth, Surrey,
UK, 4Pﬁzer Australia Pty Ltd, Sydney, NSW, Australia, 5Pﬁzer Australia
Pty Ltd,West Ryde, NSW, Australia, 6International Diabetes Institute,
Melbourne,Victoria, Australia
OBJECTIVES: To develop an epidemiological and economic
model of cardiovascular disease (CVD, comprising coronary
heart disease and stroke) that can be used to predict the future
incidence of CVD in a given population (with representative
cross-sectional data on cardiovascular risk factors) and under-
take cost-effectiveness analyses of primary preventive strategies.
METHODS: The CPM is a Markov model comprising four
health states: ‘Alive without CVD’, ‘Alive with CVD’, ‘Dead
from CVD’ and ‘Dead from non-CVD causes’. Individual sub-
jects’ risks of CVD are derived from Framingham and UKPDS
risk equations for non-diabetic and diabetic individuals, respec-
tively. The risks of non-CVD death are drawn from local mor-
tality data. To illustrate the function of the CPM, it was
populated with 1335 Australian subjects from the nationally-
representative 1999–2000 Australian Diabetes, Obesity and
Lifestyle study who were: aged 35–74 years; free of CVD; and
met current criteria for reimbursed access to statin treatment.
Follow-up was simulated until death or age 75 years. The cost-
effectiveness of atorvastatin for the primary prevention of CVD
was modelled via decision analysis, using efﬁcacy data from a
recent meta-analysis of randomized trials and Australian cost
and utility data. A 5% annual discount rate was applied.
RESULTS: The CPM predicted that of Australians currently
aged 35–74 years who were CVD-free but met criteria for
lipid-lowering treatment, 23.3% would develop CVD and
24.3% would be dead by age 75 years without statin treatment.
Atorvastatin would reduce these ﬁgures to 16.5% and 22.2%,
representing numbers needed to treat of 14.7 and 46.2 to prevent
CVD and death, respectively. The estimated ICERs were
AUD$54,100/YoLS and AUD$35,600/QALY. CONCLUSIONS:
The CPM allows for the prediction of future incidences of CVD
in a population where representative cross-sectional data on
cardiovascular risk factors are available. It can also be applied to
cost-effectiveness analyses of primary preventive interventions
for that population.
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OBJECTIVES: To assess the strength and duration of pelvic
ﬂoor muscle contraction and the ability of muscle relaxation
before and during pregnancy. METHODS: Our study focused
on examining the strength of duration and ability of relaxation
of pelvic ﬂoor muscle in cases of nulliparous young women and
pregnant women in the second and third trimesters. The mea-
surement of parameters characterizing the functional abilities
of the muscle was performed by vaginal pressure measurement
equipment. The statistical data were calculated according to
mean, standard deviation, Fisher’s exact test, T-test methods
and the results were considered to be relevant at p < 0.05.
RESULTS: Out of 119 measurements the data of 93 women
were processed. The maximum muscle strength (103.13
H2Ocm  54.12) of nulliparous women (n = 36) was signiﬁ-
cantly higher (p = 0.00348) than that of pregnant women
(n = 57); (68.3 H2Ocm  47.23). The duration of maximum
contraction in case of nulliparous women (6.4 sec  4.9)
proved to be markedly longer (p = 0.011067) than during preg-
nancy (3.98 sec  4.011). Although the maximum muscle
strength is higher in the second trimester than in the third tri-
mester the difference is not signiﬁcant. Regarding the duration
of maximum contraction no marked difference was found. A
total ability of relaxation could only be observed in one third of
the sample but no signiﬁcant difference was detected between
A420 Abstracts
the grous groups. Women who occasionally do some forms of
physical exercise showed a signiﬁcantly better muscle strength
(p = 0.02923), and women who regularly do some physical
exercises showed a signiﬁcantly longer duration of maximum
contraction (p = 0.01838) than pregnant women doing regular
or occasional exercises. CONCLUSIONS: A signiﬁcant decrease
could be observed in pregnancy as compared to nullipa-
rous young women concerning maximum pelvic ﬂoor muscle
strength and duration of maximum contraction.
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OBJECTIVES: ENJEU is a French one day, cross sectional, obser-
vational survey aimed to describe medical reasons disclosed by
men over 18 years old when visiting an urologist, to estimate the
prevalence of male sexual dysfunction (MSD) including erectile
dysfunction (ED) and to describe treatment options for ED.
METHODS:All French urologists have been contacted to partici-
pate in this national survey; 150 physicians did participate. This
sample was representative of the French urologists regarding age,
geographical distribution and practice. The survey was proposed
to 1998 patients: 1848 (92.5%) agreed to participate; analysiswas
performed on 1740 patients. Information on urologists’ practices
were collected through a questionnaire ﬁlled by the physicians.
Information related to urological disorders, sexual dysfunctions,
their treatment and their impact on the patient’s life were gathered
by a patient auto-questionnaire. Erectile dysfunction was assessed
through the single question of John B.McKinlay.RESULTS:Male
sexual dysfunction was the ﬁrst reason for visiting urologists
(14%) following prostatic diseases (62%). Eighty-eight percent
(88%) of urologists reported “usually” managing male sexual
dysfunction. Sixty-ﬁve percent (65%) of urologists reported
“systematically or often” asking their patients about eventual
MSD. The median number of patients managed for ED was ﬁve
per week. Among patients (mean age 63 +/- 14 years), 68%
(IC95% = [65.2%; 70.7%]) had ED (44% severe). Forty-one
percent (41%) did not talk about their ED to the urologist. Twenty
percent (20%) reported ejaculatory dysfunction and 13% lack
of desire. Among patients with ED, only 25% were treated (12%
with IPDE5, 8% with intracavernous injection and 5% with
treatment association). Among patients visiting for the ﬁrst time
an urologist (25%), 52% reported ED and only 8% had previ-
ously received treatment for this condition. Among patient fol-
lowed by urologists (after surgery or for medical treatment), 75%
reported ED and 39.3% were treated. CONCLUSIONS: This
survey emphasizes the high prevalence of reported, and particu-
larly unreported male sexual dysfunctions, for patients visiting
their urologists. Despite declared urologists’ interest for male
sexual dysfunction, the discrepancy between the high prevalence
of ED and the low rate of patients consulting for this condition
probably explains the low rate of patients using treatments. This
survey demonstrates the value of a routine evaluation of sexual
dysfunctions in urology clinics.
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OBJECTIVES: It is intended to describe the characteristics of the
birth defects in 52,744 births in 4 Colombian cities. A congeni-
tal malformation (CM) is deﬁned as an alteration of the mor-
phology that can be diagnosed at the pre or postnatal period. The
Colaborative Latin-American congenital malformations study
(ECLAMC) was established since 2001 at the Human Genetics
Institute at the Pontiﬁcia Universidad Javeriana. The objective of
the latter study is to do a surveillance of all newborns in order to
diagnose them promptly and to establish possible risk factors
involved in the development of CM. METHODS: We used the
data base registered from 4 different cities in Colombia during
the period between April 2001 to January 2008. The cases were
all newborns with any weight at the moment of birth or any
stillbirth above 500 gr. The controls were all healthy newborns
from the same sex as the cases. It was excluded a case or a control
if the mother did not accepted to participate in the study.
RESULTS: The population of the study was 52.744 newborns
from which 1650 (3,12%) had a MC. The majority of cases were
male and the most common CM was the group of the ear
anomalies followed by clubfoot, polydactyly, Down syndrome,
nevus, cleft palate and cardiopathies. The weight and gestational
age were less in the group of the cases compared to the controls
(p < 0,001). It was used the prognostic scale for each MC and it
was found that the majority of cases had a high risk of permanent
disability if not treated (54%). CONCLUSIONS: In this study
are reported frequencies of the CM in a sample of newborns to
4 Colombian cities found prevalence similar to the rest of the
world. These diseases contribute signiﬁcantly to the burden of
disease in our country and directly impacting infant mortality
rates.
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